John Schetz - Cresco Labs G Counsel
| CRLBF Stock | USD 1.18 0.06 4.84% |
Insider
John Schetz is G Counsel of Cresco Labs
| Age | 46 |
| Phone | 312 929 0993 |
| Web | https://www.crescolabs.com |
Cresco Labs Management Efficiency
The company has return on total asset (ROA) of 0.0399 % which means that it generated a profit of $0.0399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0635) %, meaning that it generated substantial loss on money invested by shareholders. Cresco Labs' management efficiency ratios could be used to measure how well Cresco Labs manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| BCom BAcc | Akanda Corp | 44 | |
| Mark Baldyga | Biofrontera | N/A | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Thomas Flow | Akanda Corp | 46 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Rami Levy | INC Research Holdings | 59 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| Advocate Ohayon | INC Research Holdings | 35 | |
| Amos Cohen | INC Research Holdings | 45 | |
| John Weston | cbdMD Inc | N/A | |
| Sibyl Swift | cbdMD Inc | 43 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| David Erickson | Evolus Inc | N/A | |
| Jeff Holm | Biofrontera | N/A | |
| BComm BCom | Akanda Corp | 68 | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Raymond Coffman | cbdMD Inc | 62 | |
| Hermann Lubbert | Biofrontera | 68 | |
Management Performance
| Return On Equity | -0.0635 | |||
| Return On Asset | 0.0399 |
Cresco Labs Leadership Team
Elected by the shareholders, the Cresco Labs' board of directors comprises two types of representatives: Cresco Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cresco. The board's role is to monitor Cresco Labs' management team and ensure that shareholders' interests are well served. Cresco Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cresco Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Sampson, CoFounder Director | ||
| Thomas Manning, Chairman of the Board | ||
| Charles Bachtell, CEO, Director | ||
| Ty Gent, Chief Officer | ||
| John Schetz, G Counsel | ||
| Brenna CPA, Treasury Accounting | ||
| Zach Marburger, Interim Officer | ||
| Jake Graves, Ma Relations | ||
| Dennis Olis, Chief Officer | ||
| Impola Kelli, VP Compliance |
Cresco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cresco Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0635 | |||
| Return On Asset | 0.0399 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 1.29 B | |||
| Shares Outstanding | 280.99 M | |||
| Shares Owned By Insiders | 22.87 % | |||
| Shares Owned By Institutions | 7.22 % | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 0.83 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cresco OTC Stock
Cresco Labs financial ratios help investors to determine whether Cresco OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cresco with respect to the benefits of owning Cresco Labs security.